

Reference P006

An Open-Label, Randomized, 2-Period, Single-Dose Crossover
Study to Investigate the Influence of Formulation on MK-0431
Pharmacokinetics in Healthy Male or Female Subjects

Reference P006
Healthy Subject PK and Tolerability Study Report

CLINICAL STUDY REPORT

MK-0431

An Open-Label, Randomized, 2-Period, Single-Dose Crossover Study to Investigate the Influence of Formulation on MK-0431 Pharmacokinetics in Healthy Male or Female Subjects

Generic Name:	Protocol 006
Dosage Form: MK-0431 Capsule and MK-0431 Tablet	Phase I
Indication: Diabetes	Study Design: Open, 2-Period, Single-Dose, Crossover, Comparative Bioavailability Study
Sponsor Name: Merck & Co., Inc.	
Clinical Monitor: Dr. Gary Herman	
Study Initiation Date (FPI):	11-Nov-2002
Study Completion Date (LPO):	03-Dec-2002
Investigator Name/Affiliation: Dr. Suzanne K. Swan DaVita Clinical Research 825 S. 8 th Street, Suite 300 Minneapolis, Minnesota 55404	
GCP Compliant? y/n	Yes
Clinical Study Report Date	11-Mar-2005

CLINICAL STUDY REPORT

An Open-Label, Randomized, 2-Period, Single-Dose Crossover Study to Investigate the Influence of Formulation on MK-0431 Pharmacokinetics in Healthy Male or Female Subjects

TABLE OF CONTENTS

	<u>Application Starting Page</u>
I. SYNOPSIS	10
II. COMPREHENSIVE STUDY SUMMARY	13
1. INTRODUCTION	13
2. ETHICS	15
2.1 Institutional Review Board (IRB)	15
2.2 Ethical Conduct of the Study	15
2.3 Subject Information and Informed Consent Form	15
3. INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE	15
4. STUDY HYPOTHESES AND OBJECTIVES	16
4.1 Hypotheses	16
4.2 Objectives	16
5. INVESTIGATIONAL PLAN	16
5.1 Overall Study Design and Plan: Description	16
5.2 Discussion of Study Design, Including the Choice of Control Groups	21
5.3 Selection of Study Population	21
5.3.1 Inclusion Criteria	22
5.3.2 Exclusion Criteria	22
5.3.3 Discontinuation of Subject from Therapy or Study Observation	24
5.4 Treatments	24
5.4.1 Treatments Administered and Special Diet Administered	24

TABLE OF CONTENTS (CONT.)

	Application Starting Page
5.4.2 Identity of Clinical Supplies	24
5.4.3 Method of Assigning Subjects to Treatment Groups	27
5.4.4 Selection of Doses and Timing of Dose for Each Subject	27
5.4.5 Study Blinding Procedure	27
5.4.6 Prior and Concomitant Therapies	27
5.4.7 Treatment Compliance	27
5.5 Pharmacokinetic, Safety and Tolerability Parameters	28
5.5.1 Measurements Assessed and Timing of Assessment	28
5.5.1.1 Safety Measurements	28
5.5.2 Appropriateness of Measurements	29
5.5.3 Primary and Secondary Parameter(s)	29
5.5.4 Blood for Plasma MK-0431 Drug Concentration Measurements	29
5.5.5 Analytical Methods	30
5.5.6 Pharmacokinetic Methods	30
5.6 Data Quality Assurance	30
5.7 Statistical Methods Planned in the Protocol and Determination of Sample Size	31
5.7.1 Statistical and Analytical Plans to Address Study Objectives	31
5.7.2 Determination of Sample Size and Power Analysis to Address Study Hypothesis	31
5.7.3 Statistical/Analytical Methods and Issues	31
5.8 Changes in the Conduct of the Study or Planned Analyses	32
6. STUDY AND DATA SETS ANALYZED	32
6.1 Accounting for Subjects in the Study	32
6.2 Protocol Deviations	32
6.3 Subjects Whose Treatment Was Prematurely Unblinded	32

TABLE OF CONTENTS (CONT.)

	Application Starting Page
6.4 Efficacy Populations Analyzed	32
6.5 Demographic and Other Baseline Characteristics	32
6.5.1 Baseline Characteristics	33
6.5.2 Secondary Diagnoses	33
6.5.3 Prior Therapies	33
6.5.4 Procedures	34
6.6 Concomitant Therapies	34
6.7 Measurements of Treatment Compliance	34
7. PHARMACOKINETICS AND BIOAVAILABILITY EVALUATION AND RESULTS	34
7.1 Pharmacokinetics	34
8. SAFETY EVALUATION	40
8.1 Extent of Exposure	40
8.2 Clinical Adverse Experiences	40
8.2.1 Brief Summary of Clinical Adverse Experiences	40
8.2.2 Display of Clinical Adverse Experiences	40
8.2.3 Analysis of Clinical Adverse Experiences by Body System	42
8.2.3.1 Drug-related Clinical Adverse Experiences	42
8.3 Serious Clinical Adverse Experiences	42
8.3.1 Subjects Who Discontinued Due to Clinical Adverse Experiences	42
8.4 Special Safety Analyses	42
8.5 Laboratory Adverse Experiences	42
8.6 Clinical Evaluation of Laboratory Safety Tests	43
8.7 Vital Signs, and Other Physical Observations Related to Safety	43
9. DISCUSSION	43
10. OVERALL EFFICACY AND SAFETY CONCLUSIONS	44
11. SUPPLEMENTAL TABLES, FIGURES, AND/OR NARRATIVES	44

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.